U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07046676) titled 'Pharmacogenetics-Based Study on Individualized Use of Sodium Valproate' on June 23.
Brief Summary: Sodium valproate (VPA) is a first-line prescription drug widely used in the treatment of epilepsy. However, in clinical applications, it has been found that there is a large individual variation in the blood concentration of VPA. In particular, excessively high blood drug concentrations can lead to various side effects, especially hepatotoxicity. Blood drug concentration monitoring can reduce the toxic and side effects of VPA to a certain extent and improve its effectiveness, but it is too cumbersome. A large number of studies have show...